Oncternal Therapeutics, Inc. (ONCT) News
Filter ONCT News Items
ONCT News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
Latest ONCT News From Around the Web
Below are the latest news stories about ONCTERNAL THERAPEUTICS INC that investors may wish to consider to help them evaluate ONCT as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayChecking out the biggest pre-market stock movers for Tuesday is the perfect way to get ready for another busy day of trading! |
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call TranscriptOncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call Transcript November 9, 2023 Oncternal Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.17 EPS, expectations were $-0.15. Operator: Greetings and welcome to Oncternal Therapeutics third-quarter 2023 financial results conference call. [Operator Instructions]. As a reminder, this conference is being recorded. I would now like to […] |
Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial ResultsThe first patient was dosed in our Phase 1/2 study for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitorsAdditional patients were treated in our ongoing Phase 1/2 study for ONCT-808, our ROR1-targeting autologous CAR T cell therapy, for the treatment of patients with relapsed or refractory aggressive B-cell lymphoma, including patients that have failed prior CD19 CAR |
Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial ResultsSAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2023 financial results after the U.S. financial markets close on Thursday, November 9, 2023. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a business update and discuss the Company’s third quarter financial results. The li |
Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate CancerSAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has designated ONCT-534, its novel dual-acting androgen receptor inhibitor (DAARI), as a Fast Track development program for the investigation of the treatment of patients with relapsed or refractory metastatic castration-resistant prostate cancer |
Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory BoardSAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the addition of Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board (SAB). Dr. Smith, along with the other Prostate Cancer SAB members, will help guide Oncternal’s next steps in the clinical development of its novel dual-acting androgen receptor inhibitor (DAARI), ONCT-5 |
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate CancerSAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the Phase 1/2 dose escalation/dose expansion study of ONCT-534, the company’s dual-action androgen receptor inhibitor. “The dosing of the first patient with ONCT-534 is an important milestone for patients suffering from advanced prostate cancer who have |
We're A Little Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made... |
Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory BoardSAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the establishment of its Prostate Cancer Scientific Advisory Board (SAB). The Prostate Cancer SAB is comprised of distinguished academic and industry leaders in the prostate cancer field, which will advise Oncternal as it develops its novel dual-acting androgen receptor inhibitor (DAARI), ONCT |
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial ResultsObtained U.S. FDA IND clearance for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to approved androgen receptor signaling inhibitorsDosed the first patient in our Phase 1/2 study for ONCT-808, our ROR1-targeting autologous CAR T cell therapy, for the treatment of patients with relapsed or refractory aggressive B-cell lymphomaCash runway extended into 2025, with $45.5 million in cash, cash equivalents and short |